Drug Trial Radar · NCT05063162
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
113
Actual
Start
Feb 2, 2022
Primary completion
May 6, 2027
Study completion Jul 1, 2027
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Sep 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
Conditions
- Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Interventions
RozanolixizumabDrug
* Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive pre-specified doses of rozanolixizumab.
PlaceboOther
* Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment PeriodTime frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
- For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment PeriodTime frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
- For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment PeriodTime frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
Locations
55 sites in 20 countries. Site status is shown where the registry gives one.
Mog001 50297
Scottsdale, Arizona
Mog001 50450
Palo Alto, California
Mog001 50101
Aurora, Colorado
Mog001 50553
Washington D.C., District of Columbia
Mog001 50308
Tampa, Florida
Mog001 50472
Peoria, Illinois
Mog001 50552
Baltimore, Maryland
Mog001 50243
Boston, Massachusetts
Mog001 50104
Rochester, Minnesota
Mog001 50568
San Antonio, Texas
Mog001 50473
Salt Lake City, Utah
Mog001 30022
Melbourne, Australia
Mog001 40185
Ghent, Belgium
Mog001 60033
Porto Alegre, Brazil
Mog001 40195
Hradec Králové, Czechia
Mog001 40721
Teplice, Czechia
Mog001 40170
Strasbourg, France
Mog001 40140
Göttingen, Germany
Mog001 40177
Münster, Germany
Mog001 40850
Athens, Greece
Mog001 40146
Pavia, Italy
Mog001 40629
Roma, Italy
Mog001 40646
Verona, Italy
Mog001 20068
Chiba, Japan
Mog001 20307
Isehara, Japan
Mog001 20049
Kitakyushu-shi, Japan
Mog001 20143
Kodaira, Japan
Mog001 20223
Koriyama-shi, Japan
Mog001 20224
Sendai, Japan
Mog001 20227
Sendai, Japan
Mog001 20070
Shinjuku-ku, Japan
Mog001 20032
Suita-shi, Japan
Mog001 50486
Culiacán, Mexico
Mog001 50485
Mexico City, Mexico
Mog001 40840
Bydgoszcz, Poland
Mog001 40485
Coimbra, Portugal
Mog001 40669
Porto, Portugal
Mog001 20226
Goyang-si, South Korea
Mog001 40267
Barcelona, Spain
Mog001 40161
Madrid, Spain
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.